Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Raymond James Maintains Outperform on CME Group, Lowers Price Target to $307

Author: Benzinga Newsdesk | October 13, 2025 01:07pm
Raymond James analyst Patrick O'Shaughnessy maintains CME Group (NASDAQ:CME) with a Outperform and lowers the price target from $309 to $307.

Posted In: CME

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist